PofoliaShared via Pofolia

Pharmaceutics· 2026Q1

Lipid Nanoparticles Enhance the Antichlamydial Efficacy of Ciprofloxacin and Sulfamethoxazole–Trimethoprim

József Nyári, Valéria Endrész, Katalin Burián, Dezső Péter Virok et al.

Short summary

Lipid nanoparticles carrying ciprofloxacin or sulfamethoxazole–trimethoprim were 2-4 times more effective against Chlamydia trachomatis in vitro than the free drugs.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Lipid nanoparticles carrying ciprofloxacin or sulfamethoxazole–trimethoprim were 2-4 times more effective against C. trachomatis in vitro.
  • Nano-encapsulation improved antibiotic efficacy without causing host cell cytotoxicity.
  • Formulations did not interfere with qPCR-based genomic load quantification.
  • Lipid nanoparticles are a promising strategy for enhancing antimicrobial therapies.

AI-generated from the title and abstract; the full text is not read.

Abstract

Background/Objectives:Chlamydia trachomatis (C. trachomatis) infections represent a major global public health concern, with over 100 million new cases annually. Although commonly used antibiotics like azithromycin and doxycycline are generally effective, increasing antibiotic resistance and therapeutic failures highlight the need for alternative treatments and innovative delivery systems. Methods: The efficacy of alternative antimicrobial agents, including ciprofloxacin and the combination of sulfamethoxazole and trimethoprim, was evaluated in both free and nano-formulated states. Drug encapsulation was achieved using liposomes as well as niosomal and aspasomal delivery systems. In vitro experiments were conducted on HeLa cells infected with C. trachomatis serovar D. Host cell viability and cytotoxicity were assessed using the MTT assay, while bacterial genomic load was quantified by qPCR. Results: Encapsulation significantly enhanced antimicrobial activity, with certain antibiotic-loaded lipid nanoparticles demonstrating 2–4 times greater effectiveness compared to their free counterparts. The prepared formulations exhibited no cytotoxic effects and did not interfere with PCR-based detection, confirming that observed outcomes reflect true antimicrobial activity. Conclusions: Nanocarrier-based drug delivery, particularly using lipid nanoparticles, represents a promising strategy for improving the therapeutic management of C. trachomatis infections. These findings highlight the potential of delivery platforms to enhance antibiotic performance and support the development of more effective and innovative antimicrobial therapies.

The authors' abstract, as published at the source. Pharmaceutics, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pharmaceutical Science

Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics